Compare SUVEN LIFE with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES AJANTA PHARMA SUVEN LIFESCIENCES/
AJANTA PHARMA
 
P/E (TTM) x 5.4 30.4 17.9% View Chart
P/BV x 0.8 6.3 12.7% View Chart
Dividend Yield % 2.9 0.6 514.9%  

Financials

 SUVEN LIFESCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
AJANTA PHARMA
Mar-19
SUVEN LIFESCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3381,422 23.7%   
Low Rs169898 18.9%   
Sales per share (Unadj.) Rs52.1233.5 22.3%  
Earnings per share (Unadj.) Rs6.844.0 15.5%  
Cash flow per share (Unadj.) Rs8.652.2 16.4%  
Dividends per share (Unadj.) Rs1.509.00 16.7%  
Dividend yield (eoy) %0.60.8 76.2%  
Book value per share (Unadj.) Rs65.3255.1 25.6%  
Shares outstanding (eoy) m127.2888.02 144.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.95.0 97.9%   
Avg P/E ratio x37.126.4 140.7%  
P/CF ratio (eoy) x29.622.2 133.0%  
Price / Book Value ratio x3.94.5 85.4%  
Dividend payout %22.020.5 107.3%   
Avg Mkt Cap Rs m32,272102,081 31.6%   
No. of employees `0001.16.8 15.9%   
Total wages/salary Rs m6614,307 15.4%   
Avg. sales/employee Rs Th6,132.23,022.6 202.9%   
Avg. wages/employee Rs Th611.1633.4 96.5%   
Avg. net profit/employee Rs Th803.5569.1 141.2%   
INCOME DATA
Net Sales Rs m6,63520,554 32.3%  
Other income Rs m242211 114.9%   
Total revenues Rs m6,87720,765 33.1%   
Gross profit Rs m1,6045,664 28.3%  
Depreciation Rs m221721 30.7%   
Interest Rs m3812 325.0%   
Profit before tax Rs m1,5875,143 30.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,273 56.4%   
Profit after tax Rs m8693,870 22.5%  
Gross profit margin %24.227.6 87.7%  
Effective tax rate %45.224.8 182.7%   
Net profit margin %13.118.8 69.6%  
BALANCE SHEET DATA
Current assets Rs m6,23211,812 52.8%   
Current liabilities Rs m1,4903,776 39.5%   
Net working cap to sales %71.539.1 182.8%  
Current ratio x4.23.1 133.7%  
Inventory Days Days8677 111.7%  
Debtors Days Days8382 101.2%  
Net fixed assets Rs m4,04314,398 28.1%   
Share capital Rs m127175 72.6%   
"Free" reserves Rs m8,18322,277 36.7%   
Net worth Rs m8,31022,452 37.0%   
Long term debt Rs m187 269.7%   
Total assets Rs m10,38926,962 38.5%  
Interest coverage x43.1444.3 9.7%   
Debt to equity ratio x00 728.7%  
Sales to assets ratio x0.60.8 83.8%   
Return on assets %8.714.4 60.7%  
Return on equity %10.517.2 60.7%  
Return on capital %19.523.0 85.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62210,682 52.6%   
Fx outflow Rs m1,7992,102 85.6%   
Net fx Rs m3,8228,580 44.6%   
CASH FLOW
From Operations Rs m3563,748 9.5%  
From Investments Rs m-279-2,228 12.5%  
From Financial Activity Rs m-225-1,475 15.3%  
Net Cashflow Rs m-14845 -327.9%  

Share Holding

Indian Promoters % 63.4 73.8 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.0 214.7%  
Shareholders   37,287 20,968 177.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Telecom and Healthcare Stocks Witness Selling(Closing)

Indian share markets erased the opening gains and ended marginally lower for the second consecutive day today.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 13, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS